CD36 and endometrial cancer: CD36 exhibited notably high expression in TCGA Endometrial cancer (based on T cell dysfunction scores in the core dataset), in the ICB_Zhao2019_PD1 cohort (as indicated by normalized Z-scores derived from Cox proportional hazards regression in the immunotherapy dataset), and in TAM M2 cells (based on normalized expression levels in immune-suppressive cell types) (Fig. 6A).